These Four Biotech Stocks Have Potential Upcoming Catalysts
We could see key trial results or FDA approvals in the months ahead…
Read MoreAuthor: Bret Jensen, Biotech Gems
Four Stocks for Value and Growth in an Overvalued Market
Posted by Bret Jensen, Biotech Gems | Apr 21, 2017
Two of these companies are well-managed, have solid balance sheets, are reasonably valued and pay over 6% dividend payouts…
Read MoreThese 3 Growth Stocks Could Do Well for the Rest of 2017
Posted by Bret Jensen, Biotech Gems | Apr 16, 2017
One is up some 60% since I first positively profiled it in December, living up so far to its “Home Run” potential…
Read MoreWarning: Avoid This Stock at All Costs
Posted by Bret Jensen, Biotech Gems | Mar 27, 2017
Investing in it is dangerous…
Read More3 Small Biotech Moonshots to Add to Your Portfolio
Posted by Bret Jensen, Biotech Gems | Mar 20, 2017
With the entire sector gaining steam, there’s still plenty of upside left…
Read More